The European Commission has authorized AstraZeneca’s blockbuster Tagrisso (osimertinib) as an adjuvant treatment for adult patients with early-stage epidermal growth-factor receptor-mutated nonsmall-cell lung cancer following complete tumor removal.

The approval was supported by results from a late-stage trial in which Tagrisso significantly improved disease-free survival by lowering the risk of disease recurrence by 80 percent.

Approved to treat early-stage lung cancer in more than 50 countries, Tagrisso earned $4.3 billion in global sales last year, an increase of 36 percent from the previous year.